Panaxia

Company Overview

Snapshot

Founded in September 2009, Panaxia operates with 51–200 employees. The company was acquired by Barak Investment House in March 2024.

Business overview

Panaxia Pharmaceutical Industries specializes in the research, development, and manufacturing of medical cannabis products. The company focuses on aligning medical cannabis with advanced formulation technologies and stringent pharmaceutical standards. Panaxia manufactures a range of standardized medical cannabis products, including sublingual and oral tablets, metered-dose inhalers, creams, and suppositories. Its products, manufacturing facilities, and production processes adhere to strict quality assurance procedures, serving over 30 international markets with more than 600 medical products.

Strategic signal

In March 2024, Panaxia was acquired by Barak Investment House. This acquisition signals a significant strategic shift for Panaxia, potentially integrating its medical cannabis operations within a broader investment portfolio and indicating a new phase of corporate development and market positioning.

Company Intelligence Q&A

What was the most recent significant corporate event for Panaxia?

Panaxia was acquired by Barak Investment House in March 2024.

When did Panaxia complete its merger with Herodium?

Panaxia and Herodium Investments completed their merger in October 2019. The financial terms of the merger were undisclosed.

When did Panaxia receive a marketing permit for medical cannabis products in Germany?

Panaxia was the first Israeli company to receive a marketing permit for medical cannabis products in Germany in November 2020.

What was a key strategic move for Panaxia in May 2021?

In May 2021, Panaxia sold its Israeli retail operation to focus on cannabis exports.

When did Panaxia's facility in Malta receive EU-GMP Standard certification?

Panaxia's facility in Malta was granted EU-GMP Standard certification in January 2022.